Arcus Biosciences Inc.(RCUS)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

RCUS Arcus Biosciences Inc.

未开盘 05-22 16:00:00 EDT

23.43

-0.44

-1.84%

盘后22.60

-0.83-3.54%

19:58 EDT

最高24.34	最低23.42	成交量51.65万
今开23.84	昨收23.87	日振幅3.85%
总市值29.37亿	流通市值20.77亿	总股本1.25亿
成交额1,217万	换手率0.58%	流通股本8,865万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"RCUS","market":"US","secType":"STK","nameCN":"Arcus Biosciences Inc.","latestPrice":23.43,"timestamp":1779480000000,"preClose":23.87,"halted":0,"volume":516534,"hourTrading":{"tag":"盘后","latestPrice":22.5998,"preClose":23.43,"latestTime":"19:58 EDT","volume":20188,"amount":472838.9,"timestamp":1779494295510,"change":-0.8302,"changeRate":-0.035433,"amplitude":0.035433},"delay":0,"changeRate":-0.018433179723502356,"floatShares":88651800,"shares":125349476,"eps":-3.232588,"marketStatus":"未开盘","change":-0.44,"latestTime":"05-22 16:00:00 EDT","open":23.84,"high":24.34,"low":23.42,"amount":12170078,"amplitude":0.038542,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.232588,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1779782400000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1521086400000,"exchange":"NYSE","adjPreClose":23.87,"preHourTrading":{"tag":"盘前","latestPrice":23.85,"preClose":23.87,"latestTime":"09:17 EDT","volume":899,"amount":21512.430811000002,"timestamp":1779455857417,"change":-0.02,"changeRate":-0.000838,"amplitude":0.050272},"postHourTrading":{"tag":"盘后","latestPrice":22.5998,"preClose":23.43,"latestTime":"19:58 EDT","volume":20188,"amount":472838.9,"timestamp":1779494295510,"change":-0.8302,"changeRate":-0.035433,"amplitude":0.035433},"volumeRatio":0.6372560148081331,"impliedVol":0.8117,"impliedVolPercentile":0.424},"requestUrl":"/m/hq/s/RCUS","defaultTab":"news","newsList":[{"id":"1156946115","title":"财报前瞻｜Arcus Biosciences Inc.本季度营收预计同比降19.31%，机构观点偏多","url":"https://stock-news.laohu8.com/highlight/detail?id=1156946115","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156946115?lang=zh_cn&edition=full","pubTime":"2026-04-28 13:08","pubTimestamp":1777352882,"startTime":"0","endTime":"0","summary":"Arcus Biosciences Inc.将于2026年05月05日（盘后）披露财报，市场聚焦营收与亏损收窄节奏及关键管线节点。一致预期显示，本季度公司营收预计为2,948.44万美元，同比下降19.31%；调整后每股收益预计为-0.88美元，同比改善14.94%；息税前利润预计为-1.08亿美元，同比改善5.78%。本季度一致预期指向营收2,948.44万美元，同比下滑19.31%，核心变量仍是合作与许可的确认节奏与规模，该业务的阶段性波动会直接影响单季收入表现与利润率。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"财报前瞻｜Arcus Biosciences Inc.本季度营收预计同比降19.31%，机构观点偏多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RCUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628724630","title":"Arcus Biosciences(RCUS)跌超5% 与吉利德(GILD)合作的肺癌三期研究因无效性而停止","url":"https://stock-news.laohu8.com/highlight/detail?id=2628724630","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628724630?lang=zh_cn&edition=full","pubTime":"2026-04-20 23:05","pubTimestamp":1776697554,"startTime":"0","endTime":"0","summary":"金吾财讯 | Arcus Biosciences(RCUS)跌5.63%，报2.885美元。消息面上，Arcus Biosciences周一表示，在独立数据监测委员会因无效性建议停止试验后，公司已终止其与吉利德科学(GILD)合作开展的针对转移性非小细胞肺癌的三期STAR-121研究。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250107/NmJhNzAzYmFlYjJhNGNmZDhhMTE1NWJmMTYxODM5M2UxMzU2NDM2MDM2MQ==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NmJhNzAzYmFlYjJhNGNmZDhhMTE1NWJmMTYxODM5M2UxMzU2NDM2MDM2MQ==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"299469","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","LU1778281490.HKD","BK4583","BK4588","LU1839511570.USD","LU1934455277.USD","LU0861579265.USD","LU0965509101.SGD","LU0965509010.AUD","LU2468319806.SGD","LU0965509283.SGD","BK4139","LU0289739699.SGD","LU1023059063.AUD","BK4578","LU1934455194.USD","LU2087621335.USD","IE00BKVL7J92.USD","LU1037948541.HKD","SG9999015952.SGD","IE0002270589.USD","IE00B19Z3B42.SGD","LU0234570918.USD","BK4585","LU0823416689.USD","LU0882574055.USD","LU1037948897.HKD","BK4550","LU0109394709.USD","RCUS","LU1585245621.USD","GILD","LU0114720955.EUR","BK4568","LU1674673691.USD","IE00B7SZLL34.SGD","BK4532","LU2324357040.USD","LU1674673428.USD","LU1571399168.USD","LU0122379950.USD","LU2089984988.USD","SG9999015978.USD","IE00BSNM7G36.USD","LU2112291526.USD","IE00B19Z3581.USD","SG9999015945.SGD","LU1430594728.SGD","LU1934455863.HKD","LU0058720904.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143884291","title":"Arcus Biosciences与吉利德合作协议期权权利将于2026年7月14日到期——美国证监会文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1143884291","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143884291?lang=zh_cn&edition=full","pubTime":"2026-04-20 20:04","pubTimestamp":1776686642,"startTime":"0","endTime":"0","summary":"根据最新提交至美国证券交易委员会的文件显示，Arcus Biosciences Inc.与吉利德科学此前达成的合作协议中，吉利德科学所持有的期权权利即将于2026年7月14日正式终止。\n这一关键时间节点的确认，标志着两家生物技术公司在肿瘤治疗领域战略合作关系的阶段性调整。期权权利的到期可能为双方未来合作模式带来新的变数，同时也为市场观察者提供了审视生物医药企业合作动态的重要窗口。\n合作协议条款的变更往往预示着企业战略方向的微妙转变。此次期权期限的明确，不仅关系到双方现有研发项目的权益分配，更可能对后续资本市场的估值预期产生深远影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823416689.USD","LU0122379950.USD","LU0058720904.USD","LU2089984988.USD","LU2087621335.USD","SG9999015986.USD","LU1674673428.USD","IE00BSNM7G36.USD","LU1571399168.USD","LU1066051498.USD","LU1934455194.USD","BK4583","IE00B7SZLL34.SGD","IE00BZ1G4Q59.USD","LU1839511570.USD","LU1674673691.USD","BK4578","IE00B19Z3581.USD","LU0965509101.SGD","LU1023059063.AUD","LU1066053197.SGD","SG9999015945.SGD","LU0109394709.USD","LU1037948541.HKD","LU2468319806.SGD","IE0002270589.USD","LU0882574055.USD","LU1934455863.HKD","LU0114720955.EUR","LU0965509283.SGD","LU0965509010.AUD","LU1430594728.SGD","RCUS","GILD","SG9999015952.SGD","LU1037948897.HKD","BK4532","IE00B19Z3B42.SGD","LU1778281490.HKD","LU2324357040.USD","LU0234570918.USD","BK4568","LU1057294990.SGD","BK4588","BK4566","IE00BKVL7J92.USD","LU0965508806.USD","LU0889565916.HKD","SG9999015978.USD","LU0320765992.SGD","LU0861579265.USD","BK4139","LU1585245621.USD","LU2112291526.USD","LU1061106388.HKD","BK4585","LU0289739699.SGD","BK4550","LU1934455277.USD","IE00B3T34201.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162783278","title":"财报前瞻 ｜Arcus Biosciences Inc.营收预计增25.49%，机构观点偏乐观","url":"https://stock-news.laohu8.com/highlight/detail?id=1162783278","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162783278?lang=zh_cn&edition=full","pubTime":"2026-02-18 12:59","pubTimestamp":1771390762,"startTime":"0","endTime":"0","summary":"Arcus Biosciences Inc.将于2026年02月25日公布新一季财报，市场关注营收与调整后每股收益同比改善的幅度。市场一致预期本季度营收为3626.67万美元，同比增25.49%；调整后每股收益为-1.02美元，同比改善18.09%；息税前利润为-1.21亿美元，同比改善1.23%，毛利率与净利率暂无一致预测数据可供披露。成本端投入延续使得息税前利润为-1.42亿美元，同比降35.24%，但营收较市场预期高出460.00万美元。从近期机构动态看，市场整体观点偏乐观。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻 ｜Arcus Biosciences Inc.营收预计增25.49%，机构观点偏乐观","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RCUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611110088","title":"Arcus Biosciences, Inc.盘中异动 股价大跌5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2611110088","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611110088?lang=zh_cn&edition=full","pubTime":"2026-02-14 03:29","pubTimestamp":1771010982,"startTime":"0","endTime":"0","summary":"北京时间2026年02月14日03时29分，Arcus Biosciences, Inc.股票出现异动，股价大幅下挫5.01%。Arcus Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为1.80%。其相关个股中，Moolec Science Sa C/Wts 30/01/2028、Moolec Science Sa、Phio Pharmaceuticals Corp.涨幅较大，Moolec Science Sa、Biorestorative Therapies, Inc.、Quince Therapeutics, Inc.较为活跃，换手率分别为6521.10%、341.03%、273.34%，振幅较大的相关个股有Moolec Science Sa C/Wts 30/01/2028、Moolec Science Sa、Phio Pharmaceuticals Corp.，振幅分别为121.84%、80.59%、54.33%。Arcus Biosciences, Inc.公司简介：Arcus Biosciences Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021403294297a6242a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021403294297a6242a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RCUS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611134534","title":"Arcus Biosciences, Inc.盘中异动 临近午盘股价大跌5.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2611134534","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611134534?lang=zh_cn&edition=full","pubTime":"2026-02-13 00:50","pubTimestamp":1770915012,"startTime":"0","endTime":"0","summary":"北京时间2026年02月13日00时50分，Arcus Biosciences, Inc.股票出现波动，股价大幅下跌5.31%。Arcus Biosciences, Inc.股票所在的生物技术行业中，整体跌幅为0.22%。其相关个股中，Pasithea Therapeutics Corp C/Wts 12/08/2026 、Galecto, Inc.、Karyopharm Therapeutics Inc.涨幅较大，Onconetix, Inc.、Quince Therapeutics, Inc.、Biorestorative Therapies, Inc.较为活跃，换手率分别为348.20%、186.26%、88.08%，振幅较大的相关个股有Briacell Therapeutics Corp C/Wts 26/02/2026、Polaryx Therapeutics, Inc.、Karyopharm Therapeutics Inc.，振幅分别为62.50%、60.77%、35.01%。Arcus Biosciences, Inc.公司简介：Arcus Biosciences Inc 是一家临床阶段的生物制药公司。Arcus针对不同类型的癌症进行临床试验，如肺癌、结肠直肠癌、胰腺癌等。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021300501297a5fd5c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021300501297a5fd5c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RCUS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142235368","title":"Arcus Biosciences Inc - 首次修正案将到期日延长至2030年9月1日，且不再有进一步延长权利 - SEC备案","url":"https://stock-news.laohu8.com/highlight/detail?id=1142235368","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142235368?lang=zh_cn&edition=full","pubTime":"2025-12-19 05:23","pubTimestamp":1766093017,"startTime":"0","endTime":"0","summary":"Arcus Biosciences Inc - 首次修正案将到期日延长至2030年9月1日，且不再有进一步延长权利 - SEC备案","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RCUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150596817","title":"Arcus Biosciences Inc.股价在盘前交易中下跌12%，因公司与Gilead终止癌症药物组合的高级阶段试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1150596817","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150596817?lang=zh_cn&edition=full","pubTime":"2025-12-12 21:55","pubTimestamp":1765547723,"startTime":"0","endTime":"0","summary":"Arcus Biosciences Inc.股价在盘前交易中下跌12%，因公司与Gilead终止癌症药物组合的高级阶段试验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RCUS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139444356","title":"Arcus公布第3阶段Star-221研究进展，并将研发投资集中于Casdatifan及新兴的炎症与免疫学项目","url":"https://stock-news.laohu8.com/highlight/detail?id=1139444356","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139444356?lang=zh_cn&edition=full","pubTime":"2025-12-12 21:30","pubTimestamp":1765546225,"startTime":"0","endTime":"0","summary":"Arcus公布第3阶段Star-221研究进展，并将研发投资集中于Casdatifan及新兴的炎症与免疫学项目","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RCUS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518271566","title":"Arcus Biosciences, Inc.盘中异动 早盘大幅跳水5.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518271566","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518271566?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:23","pubTimestamp":1741616619,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时23分，Arcus Biosciences, Inc.股票出现波动，股价快速下跌5.22%。Arcus Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.49%。其相关个股中，Checkpoint Therapeutics, Inc.、Mineralys Therapeutics, Inc.、Aeon Biopharma, Inc.涨幅较大，Biodexa Pharmaceuticals Plc、Scisparc Ltd.、Dogwood Therapeutics, Inc.较为活跃，换手率分别为3406.15%、721.29%、415.10%，振幅较大的相关个股有Dogwood Therapeutics, Inc.、Scisparc Ltd.、Biodexa Pharmaceuticals Plc，振幅分别为41.36%、40.24%、39.34%。Arcus Biosciences, Inc.公司简介：Arcus Biosciences Inc 是一家临床阶段的生物制药公司。Arcus针对不同类型的癌症进行临床试验，如肺癌、结肠直肠癌、胰腺癌等。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031022233998a2a9f3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031022233998a2a9f3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RCUS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516665940","title":"Arcus Biosciences, Inc.盘中异动 临近收盘大幅下跌5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516665940","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516665940?lang=zh_cn&edition=full","pubTime":"2025-03-04 04:37","pubTimestamp":1741034235,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日04时37分，Arcus Biosciences, Inc.股票出现波动，股价急速跳水5.05%。Arcus Biosciences, Inc.股票所在的生物技术行业中，整体跌幅为0.18%。其相关个股中，Abpro Holdings Inc C/Wts 12/11/2029 、Cardio Diagnostics Holdings Inc C/Wts  To Pur Com、Celularity Inc C/Wts 16/07/2026 涨幅较大，Allarity Therapeutics, Inc.、Entero Therapeutics Inc.、Aeon Biopharma, Inc.较为活跃，换手率分别为215.44%、187.68%、163.59%，振幅较大的相关个股有Radiopharm Theranostics Limited、Entero Therapeutics Inc.、Celularity Inc C/Wts 16/07/2026 ，振幅分别为119.50%、70.53%、64.88%。Arcus Biosciences, Inc.公司简介：Arcus Biosciences Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304043715989a60bf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304043715989a60bf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RCUS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516557562","title":"Arcus Biosciences, Inc.2024财年实现净利润-2.83亿美元，同比增加7.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516557562","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516557562?lang=zh_cn&edition=full","pubTime":"2025-03-02 00:01","pubTimestamp":1740844883,"startTime":"0","endTime":"0","summary":"3月2日，Arcus Biosciences, Inc.公布财报，公告显示公司2024财年净利润为-2.83亿美元，同比增加7.82%；其中营业收入为2.58亿美元，同比增加120.51%，每股基本收益为-3.14美元。机构评级：截至2025年3月2日，当前有11家机构对Arcus Biosciences, Inc.目标价做出预测，其中目标均价为32.55美元，其中最低目标价为17.00美元，最高目标价为46.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250302000218a259dd46&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250302000218a259dd46&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RCUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514378385","title":"Arcus Biosciences, Inc.盘中异动 早盘股价大涨5.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514378385","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514378385?lang=zh_cn&edition=full","pubTime":"2025-02-28 22:30","pubTimestamp":1740753029,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日22时30分，Arcus Biosciences, Inc.股票出现异动，股价大幅上涨5.77%。Arcus Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。其相关个股中，Virpax Pharmaceuticals, Inc.、Bioxcel Therapeutics, Inc.、Ensysce Biosciences, Inc.涨幅较大，Bioxcel Therapeutics, Inc.、Virpax Pharmaceuticals, Inc.、Enveric Biosciences, Inc.较为活跃，换手率分别为480.20%、239.09%、53.23%，振幅较大的相关个股有Tiziana Life Sciences Ltd、Aardvark Therapeutics, Inc.、Lexeo Therapeutics, Inc.，振幅分别为8.85%、6.22%、4.85%。Arcus Biosciences, Inc.公司简介：Arcus Biosciences Inc 是一家临床阶段的生物制药公司。Arcus针对不同类型的癌症进行临床试验，如肺癌、结肠直肠癌、胰腺癌等。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228223030abe0e9b9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228223030abe0e9b9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RCUS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156992500","title":"异动解读 | 分析师利好评级和财报数据超预期,Arcus Biosciences盘中大涨13.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=1156992500","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156992500?lang=zh_cn&edition=full","pubTime":"2025-02-26 23:13","pubTimestamp":1740582780,"startTime":"0","endTime":"0","summary":"今日盘中,Arcus Biosciences大涨13.38%,引发市场高度关注。有消息指出,这次RCUS盘中大涨的主因可能来自以下两方面:首先,券商H.C. Wainwright将该股评级从\"中性\"上调至\"买入\",并将目标价从18美元大幅上调至24美元。该行分析师认为,RCUS的实验性药物casdatifan有望成为治疗一种名为\"透明细胞肾细胞癌\"的肾癌类型的二线疗法,看好其未来前景。其次,RCUS刚刚公布的2025年第四季度财报数据也令投资者振奋。良好的财报数据反映出公司运营情况向好,增强了市场对该股的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | 分析师利好评级和财报数据超预期,Arcus Biosciences盘中大涨13.38%","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["RCUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514856450","title":"Arcus Biosciences, Inc.盘中异动 股价大涨11.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514856450","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514856450?lang=zh_cn&edition=full","pubTime":"2025-02-26 22:33","pubTimestamp":1740580398,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日22时33分，Arcus Biosciences, Inc.股票出现波动，股价大幅上涨11.23%。Arcus Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.09%。其相关个股中，Channel Therapeutics Corporation、Nutriband Inc C/Wts 、Immunoprecise Antibodies Ltd.涨幅较大，Organovo Holdings, Inc.、Cns Pharmaceuticals, Inc.、Psyence Biomedical Ltd.较为活跃，换手率分别为122.60%、92.20%、74.72%，振幅较大的相关个股有Channel Therapeutics Corporation、Cns Pharmaceuticals, Inc.、Organovo Holdings, Inc.，振幅分别为16.86%、14.35%、13.39%。Arcus Biosciences, Inc.公司简介：Arcus Biosciences Inc 是一家临床阶段的生物制药公司。Arcus针对不同类型的癌症进行临床试验，如肺癌、结肠直肠癌、胰腺癌等。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226223318a254f703&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226223318a254f703&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RCUS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106972136","title":"Arcus Biosciences第四季度每股亏损$(1.03)优于预期$(1.32)，销售额3600万美元优于预期2890万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1106972136","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106972136?lang=zh_cn&edition=full","pubTime":"2025-02-26 05:38","pubTimestamp":1740519531,"startTime":"0","endTime":"0","summary":"Arcus Biosciences 报告季度每股亏损$，优于分析师普遍预期的$，涨幅为21.97%。与去年同期每股亏损$相比，亏损减少4.63%。与去年同期销售额3100万美元相比，增长了16.13%。以上内容来自Benzinga Earnings专栏，原文如下：Arcus Biosciences  reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 21.97 percent. This is a 4.63 percent increase over losses of $ per share from the same period last year.  The company reported quarterly sales of $36.00 million which beat the analyst consensus estimate of $28.90 million by 24.57 percent.  This is a 16.13 p","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Arcus Biosciences第四季度每股亏损$(1.03)优于预期$(1.32)，销售额3600万美元优于预期2890万美元","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RCUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513773346","title":"Arcus Biosciences, Inc.盘中异动 早盘快速下跌5.01%报10.52美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513773346","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513773346?lang=zh_cn&edition=full","pubTime":"2025-02-24 23:27","pubTimestamp":1740410825,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日23时27分，Arcus Biosciences, Inc.股票出现异动，股价大幅下跌5.01%。Arcus Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.46%。其相关个股中，Pepgen Inc.、Aspire Biopharma Holdings Inc C/Wts 14/02/2030 、Psyence Biomedical Ltd C/Wts 25/01/2029涨幅较大，Pepgen Inc.、Aditxt, Inc.、Biodexa Pharmaceuticals Plc较为活跃，换手率分别为200.89%、84.63%、27.77%，振幅较大的相关个股有Pepgen Inc.、Telix Pharmaceutic、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 ，振幅分别为137.23%、55.69%、53.34%。Arcus Biosciences, Inc.公司简介：Arcus Biosciences Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224232706962ea5e3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224232706962ea5e3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","RCUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513296986","title":"Arcus Biosciences, Inc.盘中异动 急速上涨6.04%报11.39美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513296986","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513296986?lang=zh_cn&edition=full","pubTime":"2025-02-21 22:31","pubTimestamp":1740148289,"startTime":"0","endTime":"0","summary":"北京时间2025年02月21日22时31分，Arcus Biosciences, Inc.股票出现波动，股价快速拉升6.04%。截至发稿，该股报11.39美元/股，成交量8.1623万股，换手率0.08%，振幅1.49%。Arcus Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.33%。其相关个股中，Osr Holdings Inc C/Wts 09/02/2028 、Osr Holdings, Inc.、Nkgen Biotech, Inc.涨幅较大，Nkgen Biotech, Inc.、Aditxt, Inc.、蓝鸟生物较为活跃，换手率分别为69.26%、61.10%、18.92%，振幅较大的相关个股有Osr Holdings, Inc.、蓝鸟生物、Gain Therapeutics, Inc.，振幅分别为14.17%、11.05%、10.21%。Arcus Biosciences, Inc.公司简介：Arcus Biosciences Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221223129a24eb022&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221223129a24eb022&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","RCUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512485174","title":"Arcus Biosciences, Inc.盘中异动 早盘股价大涨5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512485174","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512485174?lang=zh_cn&edition=full","pubTime":"2025-02-19 22:56","pubTimestamp":1739976976,"startTime":"0","endTime":"0","summary":"北京时间2025年02月19日22时56分，Arcus Biosciences, Inc.股票出现波动，股价快速上涨5.02%。Arcus Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.50%。Arcus Biosciences, Inc.公司简介：Arcus Biosciences Inc 是一家临床阶段的生物制药公司。Arcus针对不同类型的癌症进行临床试验，如肺癌、结肠直肠癌、胰腺癌等。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219225616abd504ad&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219225616abd504ad&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RCUS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512193702","title":"HC Wainwright & Co.：维持Arcus Biosciences(RCUS.US)评级，由中性调整至中性评级, 目标价由20.00美元调整至18.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2512193702","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512193702?lang=zh_cn&edition=full","pubTime":"2025-02-19 02:22","pubTimestamp":1739902968,"startTime":"0","endTime":"0","summary":"HC Wainwright & Co.：维持Arcus Biosciences(RCUS.US)评级，由中性调整至中性评级, 目标价由20.00美元调整至18.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/19022248243327.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["RCUS"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.arcusbio.com","stockEarnings":[{"period":"1week","weight":-0.0147},{"period":"1month","weight":-0.1198},{"period":"3month","weight":0.2338},{"period":"6month","weight":0.0626},{"period":"1year","weight":1.6686},{"period":"ytd","weight":-0.0168}],"compareEarnings":[{"period":"1week","weight":0.0088},{"period":"1month","weight":0.0484},{"period":"3month","weight":0.0815},{"period":"6month","weight":0.1314},{"period":"1year","weight":0.2788},{"period":"ytd","weight":0.0934}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Arcus Biosciences, Inc.于2015年4月30日在特拉华州成立。它们是一家临床阶段的生物制药公司，致力于通过利用开发不足的生物机会创造创新的癌症免疫疗法。具体而言，他们针对特征明确的生物学途径，并提供重要的科学数据支持其调节对癌症的免疫反应的重要性，并且无论是在开发中的分子还是在存在具有次优分布的分子。为了利用这些途径，他们建立了强大而高效的发现能力，以创建和优化高度分化的小分子免疫肿瘤产品候选物。自2015年成立以来，他们已经建立了广泛的小分子和抗体产品候选组合，他们计划共同开发内部组合产品。他们已经启动了两项最先进的候选产品的临床试验，这两种产品预计将在2018年产生数据，并且他们预计在2019年上半年将从他们的第一批产品组合中获得临床数据。他们计划推出两种附加产品候选人到2018年底进入临床试验阶段。Arcus团队的成员共同工作了10多年，在Tularik Inc.，Amgen，Inc.和Flexus Biosciences，Inc.等公司中发现创新的小分子产品候选人。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.062454},{"month":2,"riseRate":0.625,"avgChangeRate":0.1292},{"month":3,"riseRate":0.375,"avgChangeRate":-0.076763},{"month":4,"riseRate":0.444444,"avgChangeRate":0.079583},{"month":5,"riseRate":0.444444,"avgChangeRate":-0.032905},{"month":6,"riseRate":0.375,"avgChangeRate":-0.018808},{"month":7,"riseRate":0.5,"avgChangeRate":0.014802},{"month":8,"riseRate":0.625,"avgChangeRate":0.061887},{"month":9,"riseRate":0.5,"avgChangeRate":0.023516},{"month":10,"riseRate":0.375,"avgChangeRate":0.01429},{"month":11,"riseRate":0.875,"avgChangeRate":0.177539},{"month":12,"riseRate":0.25,"avgChangeRate":-0.02808}],"exchange":"NYSE","name":"Arcus Biosciences Inc.","nameEN":"Arcus Biosciences Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Arcus Biosciences Inc.(RCUS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Arcus Biosciences Inc.(RCUS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Arcus Biosciences Inc.,RCUS,Arcus Biosciences Inc.股票,Arcus Biosciences Inc.股票老虎,Arcus Biosciences Inc.股票老虎国际,Arcus Biosciences Inc.行情,Arcus Biosciences Inc.股票行情,Arcus Biosciences Inc.股价,Arcus Biosciences Inc.股市,Arcus Biosciences Inc.股票价格,Arcus Biosciences Inc.股票交易,Arcus Biosciences Inc.股票购买,Arcus Biosciences Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Arcus Biosciences Inc.(RCUS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Arcus Biosciences Inc.(RCUS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}